Cardiology · Atrial FibrillationTrial Updateclinicalmid-term

Anthos and Novartis initiate LILAC-TIMI 76 trial for abelacimab in high-risk AF patients

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Novartis34 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 6:04:58 AM

Assessment confidence: 40% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The LILAC-TIMI 76 trial is crucial as it evaluates a new treatment for high-risk atrial fibrillation patients who cannot use traditional anticoagulants. Success could shift treatment paradigms and affect market dynamics significantly. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 22 ranked evidence items (1 high-relevance).

Strategic Assessment

If successful, abelacimab may capture market share from traditional anticoagulants, influencing treatment guidelines and prescribing practices. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), entity match (anthos therapeutics). In cardiology, 6 regulatory and 1 competitive items passed relevance filtering for Anthos Therapeutics.

Competitive Pressure

The most relevant competitive pressure comes from Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation (Humanexa Signals) — sponsor/company relevance (novartis). This trial could position abelacimab as a novel treatment option in a niche market of AF patients, potentially impacting existing anticoagulant therapies.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology); Sponsor/company relevance (Novartis). The trial's outcomes could influence future regulatory approvals and treatment guidelines for atrial fibrillation management.

Key Risks

Elevated medium regulatory exposure for Anthos Therapeutics could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Anthos Therapeutics through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If abelacimab proves effective, it may capture significant market share from existing anticoagulants, altering competitive positioning in the cardiology space.
Upside for Anthos Therapeutics may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Upside for Anthos Therapeutics may improve if A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov) delivers favorable follow-through.
If successful, abelacimab may capture market share from traditional anticoagulants, influencing treatment guidelines and prescribing practices.

What Would Change This Assessment

This becomes more urgent if Monitor trial enrollment progress, interim results, and any announcements regarding efficacy endpoints.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology); Sponsor/company relevance (Novartis)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Entity match (anthos therapeutics)
FDA document
View source
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
ClinicalTrials.govmedium relevance
Entity match (novartis pharmaceuticals)
FDA document
View source
Evaluation of EXL01, New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Effect of Family Participation-Based Intervention Before Coronary Artery Bypass Grafting (CABG) on Patients' Anxiety, Independence, and Psychological Resilience: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPT
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalsmedium relevance
Sponsor/company relevance (Novartis)

Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Commercial impact

medium

If abelacimab proves effective, it may capture significant market share from existing anticoagulants, altering competitive positioning in the cardiology space.

Regulatory impact

medium

The trial's outcomes could influence future regulatory approvals and treatment guidelines for atrial fibrillation management.

What to watch

Monitor trial enrollment progress, interim results, and any announcements regarding efficacy endpoints.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.